Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases
Por:
Lleo, A, Cavedo, E, Parnetti, L, Vanderstichele, H, Herukka, SK, Andreasen, N, Ghidoni, R, Lewczuk, P, Jeromin, A, Winblad, B, Tsolaki, M, Mroczko, B, Visser, PJ, Santana, I, Svenningsson, P, Blennow, K, Aarsland, D, Molinuevo, JL, Zetterberg, H, Mollenhauer, B
Publicada:
1 ene 2015
Resumen:
Alzheimer disease (AD) and Parkinson disease (PD) are the most common neurodegenerative disorders. For both diseases, early intervention is thought to be essential to the success of disease-modifying treatments. Cerebrospinal fluid (CSF) can reflect some of the pathophysiological changes that occur in the brain, and the number of CSF biomarkers under investigation in neurodegenerative conditions has grown rapidly in the past 20 years. In AD, CSF biomarkers are increasingly being used in clinical practice, and have been incorporated into the majority of clinical trials to demonstrate target engagement, to enrich or stratify patient groups, and to find evidence of disease modification. In PD, CSF biomarkers have not yet reached the clinic, but are being studied in patients with parkinsonism, and are being used in clinical trials either to monitor progression or to demonstrate target engagement and downstream effects of drugs. CSF biomarkers might also serve as surrogate markers of clinical benefit after a specific therapeutic intervention, although additional data are required. It is anticipated that CSF biomarkers will have an important role in trials aimed at disease modification in the near future. In this Review, we provide an overview of CSF biomarkers in AD and PD, and discuss their role in clinical trials.
Filiaciones:
Lleo, A:
Hosp Santa Creu & Sant Pau, Inst Invest Biomed, Dept Neurol, Barcelona 08025, Spain
Cavedo, E:
IRCCS, Ist Ctr San Giovanni di Dio Fatebenefratelli, Milan, Italy
Parnetti, L:
Univ Perugia, Osped Santa Maria Misericordia, Perugia, Italy
Herukka, SK:
Univ Eastern Finland, Joensuu, Finland
Kuopio Univ Hosp, Kuopio, Finland
Andreasen, N:
Karolinska Inst, Solna, Sweden
Ghidoni, R:
IRCCS, Ist Ctr San Giovanni di Dio Fatebenefratelli, Milan, Italy
Lewczuk, P:
Univ Klinikum Erlangen, Erlangen, Germany
Univ Erlangen Nurnberg, Nurnberg, Germany
Jeromin, A:
Quanterix, Lexington, MA 02421 USA
Winblad, B:
Karolinska Inst, Solna, Sweden
Tsolaki, M:
Aristotle Univ Thessaloniki, Thessaloniki, Greece
Mroczko, B:
Med Univ Bialystok, Bialystok, Poland
Visser, PJ:
Maastricht Univ, Maastricht, Netherlands
Santana, I:
Univ Coimbra, P-3000 Coimbra, Portugal
Svenningsson, P:
Karolinska Inst, Solna, Sweden
Blennow, K:
Univ Gothenburg, Sahlgrenska Acad, Gothenburg, Sweden
Aarsland, D:
Stavanger Univ Hosp, Stavanger, Norway
Zetterberg, H:
Univ Gothenburg, Sahlgrenska Acad, Gothenburg, Sweden
Mollenhauer, B:
Paracelsus Elena Klin, Kassel, Germany
|